Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment

Introduction: Treatment options for neuroendocrine tumors (NETs) are rarely curative, as NETs frequently show resistance to medical therapy. The use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signaling. In this context, the an...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitali, Eleonora, Boemi, Ilena, Tarantola, Giulia, Piccini, Sara, Zerbi, Alessandro, Veronesi, Giulia, Baldelli, Roberto, Mazziotti, Gherardo, Smiroldo, Valeria, Lavezzi, Elisabetta, Spada, Anna, Mantovani, Giovanna, Lania, Andrea G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464161/
https://www.ncbi.nlm.nih.gov/pubmed/32748870
http://dx.doi.org/10.3390/cancers12082143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464161/
https://www.ncbi.nlm.nih.gov/pubmed/32748870
http://dx.doi.org/10.3390/cancers12082143

Ejemplares similares